the treatment of patients with advanced kidney cancer with four targeted drugs: sorafenib, sunitinib, bevacizumab and temsirolimus (see In the news on p658). The decision is based on cost and the fact that these agents are not curative, although they can increase progression-free survival.
Debate over the affordability of cancer drugs is not limited to the UK: it is becoming a worldwide issue. With more targeted, and therefore relatively expensive, drugs set to enter the clinic, the cost of cancer treatment will continue to increase for the next few years. In an ideal world, all patients with cancer should have access to the best treatments whether they are curative or not but, when there is not enough money, Undoubtedly this debate will rage on for sometime yet, but hopefully clinicians, patients, payers and pharmaceutical companies will find a way around the need to reject drugs based on their cost. 
